Compounds > adenosine-5'-carboxaldehyde
Page last updated: 2024-12-08

adenosine-5'-carboxaldehyde

Description

adenosine-5'-carboxaldehyde: potent inhibitor of S-adenosyl-L-homocysteine hydrolase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5'-dehydroadenosine : A member of the class of adenosines that is 5'-dehydro derivative of adenosine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID443234
CHEMBL ID308037
CHEBI ID1958
SCHEMBL ID4776904
MeSH IDM0215151

Synonyms (18)

Synonym
CHEMBL308037 ,
bdbm50051435
5''-deoxy-5''-oxoadenosine
5''-dehydroadenosine
5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-carbaldehyde
(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-carbaldehyde
9-beta-d-ribo-pentodialdo-1,4-furanosyl-9h-purin-6-amine
3110-98-3
CHEBI:1958 ,
5'-deoxy-5'-oxoadenosine
5'-dehydroadenosine
adenosine, 5'-deoxy-5'-oxo-
adenosine-5'-carboxaldehyde
SCHEMBL4776904
Q27105535
DTXSID20953201
9-(pentodialdo-1,4-furanosyl)-9h-purin-6-amine
(2s,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carbaldehyde
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
adenosinesAny purine ribonucleoside that is a derivative of adenosine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AdenosylhomocysteinaseRattus norvegicus (Norway rat)Ki0.04300.00840.02570.0430AID200096
AdenosylhomocysteinaseHomo sapiens (human)Ki0.04030.00000.18991.9300AID199279; AID199468; AID199471
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
one-carbon metabolic processAdenosylhomocysteinaseHomo sapiens (human)
S-adenosylmethionine cycleAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
adenosylselenohomocysteinase activityAdenosylhomocysteinaseRattus norvegicus (Norway rat)
adenosylhomocysteinase activityAdenosylhomocysteinaseHomo sapiens (human)
protein bindingAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytosolAdenosylhomocysteinaseRattus norvegicus (Norway rat)
nucleusAdenosylhomocysteinaseHomo sapiens (human)
endoplasmic reticulumAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
melanosomeAdenosylhomocysteinaseHomo sapiens (human)
extracellular exosomeAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID8423750% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK) VMW 1837 strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID125185Cytostatic activity against human lymphocyte Molt 4/clone 8 cell line1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199140Inhibition of human placental S-Adenosyl-homocysteine hydrolase at 1.0 (uM) concentration1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID200096Inhibitory activity against recombinant rat liver S-adenosyl-homocysteine hydrolase1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Adenosine-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID200099Rate constant for recombinant rat liver S-adenosyl-homocysteine hydrolase inactivation1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Adenosine-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID8479250% effective concentration required to reduce herpes simplex virus-2 (HSV-2 G strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID218513Effective concentration required to reduce vesicular stomatitis virus (VSV)-induced cytopathicity in vero cells1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID218509Effective concentration required to reduce coxsackie virus B4-induced cytopathicity in vero cells1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID232028Second order rate constant for AdoHcy Hydrolase inactivation estimated as the ratio of k2/Ki1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Aristeromycin-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID199467Inhibition of S-adenosyl-L-homocysteine hydrolase, dissociation constant.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Inactivation of S-adenosyl-L-homocysteine hydrolase by amide and ester derivatives of adenosine-5'-carboxylic acid.
AID199589Apparent inactivation rate constant (k2) for S-adenosyl-L-homocysteine hydrolase1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Aristeromycin-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID218510Effective concentration required to reduce parainfluenza-3-induced cytopathicity in vero cells1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199279concentration dependent inhibition of S-Adenosyl-homocysteine hydrolase was determined by Kitz and Wilson method1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID200098Ratio value is k2/Ki (1/nM 1/min)1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Adenosine-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID8423650% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK) B2006 strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID98560Cytostatic activity against murine leukemia L1210 cell line1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID9076150% effective concentration required to reduce cytomegalovirus (CMV Davis strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199471Binding affinity towards purified recombinant human placental S-adenosyl-L-homocysteine hydrolase1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Aristeromycin-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase.
AID46557Cytostatic activity against human lymphocyte CEM cell line1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID21797550% effective concentration required to reduce vaccinia virus-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199142Inhibition of human placental S-Adenosyl-homocysteine hydrolase at 10.0 (uM) concentration; No activity detected1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199468Inhibition of S-adenosyl-L-homocysteine hydrolase, inactivation rate constant.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Inactivation of S-adenosyl-L-homocysteine hydrolase by amide and ester derivatives of adenosine-5'-carboxylic acid.
AID199139Inhibition of human placental S-Adenosyl-homocysteine hydrolase at 0.1 (uM) concentration1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199138Inhibition of human placental S-Adenosyl-homocysteine hydrolase at 0.01 (uM) concentration1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID218512Effective concentration required to reduce sindbis virus-induced cytopathicity in vero cells1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199144Inhibition of human placental S-Adenosyl-homocysteine hydrolase at 100.0 (uM) concentration; No activity detected1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID231779Ratio of concentration and time dependent inhibition of AdoHcy Hydrolase.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID229491Inhibition of S-adenosyl-L-homocysteine hydrolase, second order rate constant k2/KI1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Inactivation of S-adenosyl-L-homocysteine hydrolase by amide and ester derivatives of adenosine-5'-carboxylic acid.
AID9076050% effective concentration required to reduce cytomegalovirus (CMV AD-169 strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID63602Minimum inhibitory concentration required to effect a microscopically visible change of cell morphology in human embryonic skin-muscle (E6SM) cell culture.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID218511Effective concentration required to reduce reovirus-1-induced cytopathicity in vero cells1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID8588350% effective concentration required to reduce herpes simplex virus-1 (HSV-1 KOS strain)-induced cytopathicity1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID71883Cytostatic activity against murine mammary carcinoma FM3A cell line1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID199145Time dependent inhibition of S-Adenosyl-homocysteine hydrolase was determined by Kitz and Wilson method1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID8253250% Cytostatic concentration required to inhibit human erythroleukemic (HEL) cell proliferation1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.40 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0310nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		2.0310organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0310pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
cytarabine
[no description available]		2.0310beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		2.03106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		6.9810adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
[no description available]		2.0310
thymine arabinoside
thymine arabinoside: selectively inhibits replication of herpes simplex virus		2.0310N-glycosyl compound
edoxudin
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
n-(2-(hydroxyethoxy)methyl)-5-methyluracil
N-(2-(hydroxyethoxy)methyl)-5-methyluracil: structure given in first source		2.0310
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil: structure given in first source		2.0310
9-(2,3-dihydroxypropyl)adenine, (s)-isomer
[no description available]		1.9910
5-hydroxymethyl-2'-deoxyuridine
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
msh release-inhibiting hormone
[no description available]		2.0310oligopeptide
5-hydroxy-2'-deoxyuridine
5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine		2.0310
adenosine-5'-carboxylic acid
[no description available]		1.9910purine nucleoside
5-formyl-2'-deoxyuridine
5-formyl-2'-deoxyuridine: structure given in first source		2.0310
5'-n-methylcarboxamideadenosine
5'-N-methylcarboxamideadenosine: RN given refers to (beta-D)-isomer		1.9910
5-nitro-2'-deoxyuridine
[no description available]		2.0310
5-vinyl-2'-deoxyuridine
5-vinyl-2'-deoxyuridine: structure		2.0310
1-deazaadenosine
1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source		1.9910
5-propyl-2'-deoxyuridine
5-propyl-2'-deoxyuridine: RN given refers to parent cpd		2.0310
brivudine
brivudine: anti-herpes agent		2.4120
5-ethynyl-2'-deoxyuridine
5-ethynyl-2'-deoxyuridine: structure in first source		2.0310
5-cyano-2'-deoxyuridine
5-cyano-2'-deoxyuridine: structure in first source		2.0310
5-(2-iodovinyl)-2'-deoxyuridine
[no description available]		2.0310
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.03102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
9-((2-phosphonylmethoxy)ethyl)guanine
9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source		2.0310phosphoethanolamine
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9910
Experimental Mammary Neoplasms
[description not available]		01.9910
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		01.9910
chemdatabank.com